CRIS Current Research Information System

LANDUZZI, LORENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.632
EU - Europa 2.538
AS - Asia 985
AF - Africa 141
SA - Sud America 5
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 7.307
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.596
GB - Regno Unito 601
IT - Italia 591
CN - Cina 446
DE - Germania 384
VN - Vietnam 369
SE - Svezia 284
CH - Svizzera 122
UA - Ucraina 113
IN - India 112
IE - Irlanda 102
FR - Francia 89
RU - Federazione Russa 84
TG - Togo 57
ZA - Sudafrica 47
EE - Estonia 45
BG - Bulgaria 38
CA - Canada 36
BE - Belgio 28
JO - Giordania 22
FI - Finlandia 14
CI - Costa d'Avorio 13
RO - Romania 13
NG - Nigeria 11
NL - Olanda 10
SC - Seychelles 9
JP - Giappone 8
IR - Iran 7
CL - Cile 5
GR - Grecia 5
HK - Hong Kong 5
DK - Danimarca 4
HR - Croazia 4
SG - Singapore 4
AU - Australia 3
EG - Egitto 3
A2 - ???statistics.table.value.countryCode.A2??? 2
ES - Italia 2
ID - Indonesia 2
MD - Moldavia 2
PL - Polonia 2
TR - Turchia 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
IL - Israele 1
IQ - Iraq 1
KR - Corea 1
LB - Libano 1
NZ - Nuova Zelanda 1
SA - Arabia Saudita 1
SN - Senegal 1
Totale 7.307
Salva come PNG Salva come JPEG
Città #
Southend 526
Fairfield 511
Chandler 481
Ashburn 286
Ann Arbor 240
Woodbridge 237
Houston 217
Seattle 205
Wilmington 205
Dong Ket 198
Cambridge 166
Shanghai 164
Princeton 133
Bern 112
Dublin 102
Bologna 100
Jacksonville 75
Frankfurt am Main 67
Lomé 57
Westminster 53
Bremen 52
Nanjing 47
Padova 45
Berlin 41
Sofia 38
Beijing 32
San Diego 31
Shenyang 29
Brussels 27
Milan 27
Jinan 26
Saint Petersburg 26
Des Moines 24
Turin 24
Ottawa 23
Redmond 23
Redwood City 23
Amman 22
Boardman 22
Hebei 19
Nanchang 19
Changsha 17
Guangzhou 16
Mülheim 16
Abidjan 13
Florence 12
Jiaxing 12
Tianjin 12
Abeokuta 10
Bühl 10
Verona 10
Dearborn 9
Helsinki 9
London 9
Mahé 9
Catanzaro 8
Falls Church 8
Kuban 8
Los Angeles 8
Phoenix 8
Zhengzhou 8
Amsterdam 7
Crocetta 7
Kerpen 7
Leawood 7
Rome 7
Crotone 6
Haikou 6
Lanzhou 6
Moscow 6
Naples 6
New York 6
Parma 6
Taizhou 6
Tokyo 6
Bulle 5
Dallas 5
Delhi 5
Ningbo 5
Reggio Nell'emilia 5
Taiyuan 5
Vicenza 5
Chieti 4
Hong Kong 4
Lappeenranta 4
Montreal 4
Muizenberg 4
Olalla 4
Paris 4
Washington 4
Zanjan 4
Bagni 3
Boydton 3
Buffalo 3
Cagliari 3
Carrara 3
Castenaso 3
Cavenago Di Brianza 3
Codigoro 3
Hangzhou 3
Totale 5.154
Salva come PNG Salva come JPEG
Nome #
IFN-γ and CD38 in Hyperprogressive Cancer Development 279
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft 223
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations 208
A multi-DNA preventive vaccine for p53/Neu driven cancer syndrome 198
Cancer Vaccines Co-Targeting HER2/Neu and IGF1R 163
Advances in preclinical therapeutics development using small animal imaging and molecular analyses: the gastrointestinal stromal tumors model. 151
Integrated molecular characterization of patient-derived models reveals therapeutic strategies for treating CIC-DUX4 sarcoma 151
CD99 Acts as an Oncosuppressor in Osteosarcoma. 148
Preclinical therapy of disseminated HER-2+ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. 146
Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy 144
Endothelin-3 production by human rhabdomyosarcoma: A possible new marker with a paracrine role. 140
Apc10.1: an ApcMin/+ intestinal cell line with retention of heterozygosity. 139
A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy 139
Virus-like particle display of HER2 induces potent anti-cancer responses 136
An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas. 132
Biological indicators of prognosis in Ewing’s sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP). 132
Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. 132
Antimetastatic activity of a preventive cancer vaccine. 126
Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model 126
Immunological prevention of a multigene cancer syndrome 124
Immunoprevention and immunotherapy of mammary carcinoma 123
Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor 123
HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines 120
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER-2. 120
Human responses against HER-2-positive cancer cells in human immune system-engrafted mice. 119
Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. 116
Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug. 115
Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis 115
ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity 114
Targeting CD99 compromises the oncogenic effects of the chimera EWS-FLI1 by inducing re-expression of zyxin and inhibition of Gli1 activity 113
In silico modeling and in vivo efficacy of cancer preventive vaccinations 111
Circulating miR34a levels as a potential biomarker in the follow-up of Ewing sarcoma 111
Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers. 109
Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer 108
Evaluation of Modified PEG-Anilinoquinazoline Derivatives as Potential Agents for EGFR Imaging in Cancer by Small Animal PET. 108
Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. 107
APC10.1 cells as a model for assessing the efficacy of potential chemopreventive agents in the ApcMin mouse model in vivo. 107
Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells 106
Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. 106
TRAF6 regulates proliferation and differentiation of skeletal myoblasts 103
OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis 103
High metastatic efficiency of human sarcoma cells in Rag2/gamma c double knockout mice provides a powerful test system for antimetastatic targeted therapy 103
Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. 102
Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. 101
HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response 101
Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells 101
Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing’s sarcoma. 101
Evaluation of metastatic burden and recovery of human metastatic cells from a mouse model 97
Molecular and cellular biology of rhabdomyosarcoma 95
Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12 engineered allogeneic cell vaccine 94
Vaccines and other immunological approaches for cancer immunoprevention 92
Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent 91
Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas 90
RIP2 regulates growth and differentiation of normal myoblasts and of rhabdomyosarcoma cells. 85
Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system 84
Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma 80
NVE-BEZ235 as a new therapeutic option for sarcomas. 79
Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy. 74
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression 70
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC 68
Patient Derived Xenografts for Genome-Driven Therapy of Osteosarcoma 67
Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells 57
HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy 54
Up-regulation of EphB and ephrin-B expression in rhabdomyosarcoma. 44
Synovial Sarcoma Preclinical Modeling: Integrating Transgenic Mouse Models and Patient-Derived Models for Translational Research 42
Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine 39
CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality 35
IL-1 Family Members in Bone Sarcomas 15
Innovative Breakthroughs for the Treatment of Advanced and Metastatic Synovial Sarcoma 14
Totale 7.569
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.361
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.361
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201995 0 0 0 0 0 0 0 0 0 0 20 75
2019/20201.832 202 47 24 91 194 179 243 279 260 136 87 90
2020/20211.244 190 62 35 64 26 48 43 132 130 57 49 408
2021/20221.471 122 48 104 58 123 86 39 107 81 128 337 238
2022/20231.923 183 227 111 277 123 132 67 104 278 73 176 172
2023/2024594 28 80 28 47 38 63 36 221 17 32 4 0
Totale 7.569